Login to Your Account



Other News To Note


Wednesday, September 25, 2013
• Chrysalis Biotherapeutics Inc., of Galveston, Texas, received a $1 .5 million contract from the National Cancer Institute to continue its development of Chrysalin, a naturally occurring regenerative peptide, to mitigate radiotherapy-induced damage to normal brain tissue.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription